Kathy S. Albain

Breast and lung oncologist who led the trials showing gene tests can guide chemotherapy decisions.

Medical oncologist who led SWOG 8814 (Oncotype DX in node-positive disease) and co-led RxPONDER, and chaired SWOG trials in stage III lung cancer.

Role

Vice Chair, Clinical Trials Partnerships, SWOG; Professor of Medicine, Loyola University Chicago

Institution

Specialisms

Breast cancerLung cancerGenomic assays

Profiles

Papers

Title	Journal	Year
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial	Lancet Oncology	2010
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer	New England Journal of Medicine	2021